HR Execs on the Move


 
Founded in 2017 by Carolyn Witte and Felicity Yost, Tia is bringing the new standard of care for women for women in NY, LA, SF and PHX. Blending in-person and virtual care services, Tia`s “Whole Woman, Whole Life” care model fuses gynecology, primary care, mental health and evidence-based wellness services to treat women comprehensively. By bringing collaborative, comprehensive, and compassionate care, Tia is raising the bar for women and empowering them to achieve optimal health, on their terms.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.asktia.com
  • 548 Market Street Suite 45295
    San Francisco, CA USA 94104
  • Phone: 855.586.1306

Executives

Name Title Contact Details
Mary White
Senior Director Growth Marketing Profile
Daria Burke
Global Chief Marketing Officer Profile

Similar Companies

Biological Test Center

Biological Test Center is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midwest Medical Svc

Midwest Medical Svc is a Charleston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DxNA

DxNA is a St George, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Leprosy Missions

American Leprosy Missions is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.